'Ethnic minorities less likely to receive optimal end-of-life care within UK healthcare system'
Research indicates that existing policies have disproportionately affected individuals from ethnically diverse groups, leading to unfavourable outcomes
Ethnic minorities in the UK have experienced disparities in end-of-life care, particularly during the Covid pandemic.
Research indicates that existing policies have disproportionately affected individuals from ethnically diverse groups, leading to unfavourable outcomes, Care Home Professional reported.
Contributing to these disparities is a lack of understanding among healthcare providers about the difference between equal and equitable care, resulting in distress and unequal treatment.
To bridge this knowledge gap and enhance end-of-life care, a team led by Sabrina Bajwah from the Cicely Saunders Institute at King's College London's Faculty of Nursing, Midwifery & Palliative Care has developed an educational film.
The film, funded by the Medical Research Foundation, was collaboratively created with a focus group comprising ethnically diverse patients and health professionals.
The work offers timely guidance to bridge the divide between individuals who receive the best and most comprehensive end-of-life care and those who receive the least and poorest care.
The film, while impactful, remains sensitive in its approach.
It incorporates the voices and experiences of patients, bereaved relatives, and healthcare professionals to foster a deeper understanding of the unique needs of individuals from ethnically diverse backgrounds, the importance of addressing these needs, the distinction between equality and equity, and strategies to deliver equitable care.
Bajwah, the project lead and a clinical senior lecturer, highlights the significance of reducing the gap between the best and worst end-of-life experiences.
Although the research and film primarily focus on ethnically diverse groups, the recommendations for reducing health inequalities are relevant to all underserved populations across different healthcare specialties and settings.
Toby Porter, chief executive of Hospice UK, commends the film as an essential and well-crafted resource.
He emphasises the importance of mandatory viewing among palliative care professionals, as it effectively conveys the need for equitable treatment within the palliative care system.
Porter acknowledges the efforts of hospice colleagues striving for more equitable access to care, underscoring the significance of recognising and addressing existing disparities to drive progress and improvement.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.